SCHEMBL3100284

SCHEMBL3100284

N#Cc1cc(-c2ccc(Cl)cc2Cl)c(-c2ccc(Cl)cc2)[nH]c1=O

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.50
MCL1 Q07820 1/20 0.49
CNR1 P21554 13/20 0.46
CNR2 P34972 12/20 0.44
MET P08581 2/20 0.43
KDR P35968 1/20 0.43
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
ALDH1A1 P00352 2/20 0.42
GAA P10253 2/20 0.42
HPGD P15428 2/20 0.42
LMNA P02545 1/20 0.42
GALR3 O60755 1/20 0.42
EGFR P00533 1/20 0.41
CDK4 P11802 1/20 0.41
BRAF P15056 1/20 0.41
CDK6 Q00534 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1404496 0.89 CNR1 (0.49) KDM4EMCL1CNR1CNR2ALDH1A1
SCHEMBL19835567 0.87 MCL1 (0.55) KDM4EMCL1CNR1MEN1KMT2A
SCHEMBL5363847 0.82 KDM4E (0.59) KDM4EMCL1CNR1METKDR
SCHEMBL5363935 0.82 CNR1 (0.51) KDM4EMCL1CNR1CNR2ALDH1A1
SCHEMBL5363205 0.82 KDM4E (0.49) KDM4EMCL1CNR1CNR2MEN1
SCHEMBL19835568 0.81 KDM4E (0.51) KDM4EMCL1CNR1MEN1KMT2A
SCHEMBL3621034 0.80 CNR1 (0.46) KDM4EMCL1CNR1CNR2MEN1
SCHEMBL3401285 0.80 MCL1 (0.45) KDM4EMCL1CNR1CNR2MEN1
SCHEMBL1404528 0.78 KDM4E (0.51) KDM4EMCL1CNR1CNR2ALDH1A1
SCHEMBL9587750 0.74 KDM4E (0.73) KDM4EMCL1CNR1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362045-B2 5,6-diaryl pyridines substituted in the 2- and 3-position, preparation thereof and therapeutic use thereof SANOFI (FR) 2013-01-29 US disclosed
US-20100256202-A1 5,6-DIARYL PYRIDINES SUBSTITUTED IN THE 2- AND 3-POSITION, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2010-10-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256202-A1 5,6-DIARYL PYRIDINES SUBSTITUTED IN THE 2- AND 3-POSITION, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF ALK, ROS1, CYP11B2 KDM4E 736/4885MCL1 1351/4885CNR1 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.